Brief: Xbrane Biopharma Gets Scientific Advice From FDA On Development Of Xdivane
27/09/2024 10:05
Sept 27 (Reuters) - Xbrane Biopharma AB XBRANE.ST :
* HAS RECEIVED SCIENTIFIC ADVICE FROM US FOOD AND DRUG
ADMINISTRATION (FDA) ON DEVELOPMENT OF ITS OPDIVO® BIOSIMILAR
CANDIDATE XDIVANE TM
* FDA CONCURS WITH EMAS FEEDBACK AND FIND XBRANES PROPOSED
STREAMLINED CLINICAL DEVELOPMENT PLAN ADEQUATE TO SUPPORT A
FUTURE BLA
Source text for Eikon: ID:nMFN18yMx0
Further company coverage: XBRANE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))